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ABSTRACT A subset of human T lymphocytes ex-
presses the natural killer (NK) cell-associated receptor
CD56 and is capable of major histocompatibility complex
(MHC)–unrestricted cytotoxicity against a variety of au-
tologous and allogeneic tumor cells. CD56 T cells have
shown potential for immunotherapy as antitumor cyto-
toxic effectors, but their capacity to control adaptive
immune responses via cytokine secretion is unclear. We
have examined the inducibility of CD56 T cells from
human blood in vitro and compared the kinetics of Th1,
Th2, and regulatory cytokine secretion by CD56 T cells
with those of conventional CD56 T cells. CD56 was
induced on CD8 and CD4CD8 T cells by CD3/T-cell
receptor (TCR)-mediated activation, particularly when
grown in the presence of interleukin (IL)-2. Activation-
induced CD56 T cells proliferated less vigorously but k
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uman Immunology 67, 863–873 (2006)
American Society for Histocompatibility and Immunogenetics, 2006
ublished by Elsevier Inc.isplayed enhanced natural cytotoxicity compared with
D56 T cells. CD56 T cells released interferon-
IFN-) and interleukin-13 (IL-13), but not IL-10, upon
CR stimulation. Flow cytometric analysis demonstrated
hat, compared with CD56 T cells, elevated proportions
f CD56 T cells expressed IFN-, IL-4, and IL-13
ithin hours of activation. These acquired cytolytic and
ytokine secretion activities of CD56 T cells make them
otential targets for immunotherapy for infectious and
mmune-mediated disease. Human Immunology 67,
63–873 (2006). © American Society for Histocompat-
bility and Immunogenetics, 2006. Published by Elsevier
nc.
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ines; cytotoxicity; kineticsABBREVIATIONS
IFN interferon
IL interleukin
mAb monoclonal antibody
MHC major histocompatibility complex
NK natural killerKT natural killer T
BMC peripheral blood mononuclear cell
HA phytohemagglutinin
MA phorbol myristate acetate
CR T-cell receptorNTRODUCTION
subset of human T lymphocytes expresses the cell-
urface, immunoglobulin superfamily molecule, CD56,
hich is typically expressed by natural killer (NK)
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Received May 31, 2006; revised July 15, 2006; accepted August 17,ells, neurons, and some tumor cells [1, 2]. CD56 T
ells are heterogenous in nature and include CD4,
D8, and CD4CD8 cells expressing  or 
ajor histocompatibility complex (MHC) or CD1d-
estricted T-cell receptors (TCRs), and various combi-
ations of NK cell receptors (NKRs), including CD16,
D56, CD94/NKG2, CD161, NKG2D, and killer im-
unoglobulinlike receptors [3–5]. They generally ac-
ount for less that 5% of peripheral blood T cells and
p to 50% of T cells in the liver [6, 7] and in the
ntestine [8 –10]. Functionally, CD56 T cells display
roperties of both NK cells and T cells. They are
0198-8859/06/$–see front matter
doi:10.1016/j.humimm.2006.08.292
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864 J. Kelly-Rogers et al.apable of potent perforin/granzyme-mediated killing
f a variety of tumor target cells in vitro and in vivo [3,
1, 12]. This MHC-unrestricted cytotoxicity does not
equire prior antigenic exposure but appears to involve
he ligation of stimulatory NKRs and/or the TCR, and
xposure to cytokines of diverse cellular origins, in-
luding interferon- (IFN-), interleukin-1 (IL-1) and
L-2 [11], IFN-, IL-2, IL-12 and/or IL-18 [13], IL-2
nd IL-12 [13–17], and IL-15 [4]. The cytotoxic ac-
ivities of CD56 T cells against autologous and allo-
eneic leukemic cells are reported to be superior to
hose of NK cells and lymphokine activated killer cells
11, 18, 19], and phase I trials for leukemia by using
utologous CD56 T cells generated ex vivo by CD3
timulation of peripheral blood mononuclear cells (PB-
Cs) in the presence of cytokines (cytokine-induced
iller cells) are under way [19 –22].
In addition to NK-like cytotoxicity, CD56 T cells
re capable of TCR-mediated and MHC- or CD1d-
estricted cytotoxicity and secretion of cytokines, in-
luding IFN-, TNF-, and IL-4, which promote Th1
r Th2 adaptive immune responses [3–5, 13, 15, 23–
5]. The dual innate and adaptive immune functions
lace CD56 T cells alongside natural killer T (NKT)
ells and subsets of  T cells as frontline innate
mmune effectors and potential regulators of adaptive
mmune responses against microorganisms and tumors
26, 27]. These properties make CD56 T cells attrac-
ive potential targets for therapy for infectious and
mmune-mediated diseases as well as cancer. In support
f this notion, numerical and functional deficiencies
nd phenotypic alterations of CD56 T cells have been
eported in patients with various infectious and auto-
mmune diseases and cancer [23, 28 –32].
In the present study, we have investigated the po-
ential of human CD56 T cells as initiators and
egulators of adaptive immune responses by examining
he kinetics of their inducibility from human blood in
itro and comparing their functional properties with
hose of conventional CD56 T cells. We demonstrate
hat CD56 expression can be induced on CD56 T
ells by CD3/TCR-mediated activation and that
ctivation-induced CD56 T cells display MHC-
nrestricted killing of target cells and IFN- and IL-
3, but not IL-10 secretion. Flow cytometric analysis
emonstrated that CD56 T cells more frequently
xpressed IFN-, IL-4, and IL-13 than CD56 T cells
n the first 24 hours following stimulation. Thus, in
ddition to acquiring innate cytolytic activities, the
nduction of CD56 on T cells is frequently associated
ith enhanced capacity to stimulate and polarize adap-ive immune responses. mATERIALS AND METHODS
ubjects
lood samples were obtained from healthy donors. PB-
Cs were prepared by standard Lymphoprep (Nycomed,
slo, Norway) density gradient centrifugation. Ethical
pproval for this study was obtained from the Ethics
ommittee of the National University of Ireland,
aynooth.
ntibodies and Flow Cytometry
onoclonal antibodies (mAb) specific for human CD3,
D4, CD8, CD56, TCR, TCR, CD161,
D69, HLA-DR, CD25, CD45RO, the invariant
24J18 TCR -chain found on CD1d-restricted
KT cells [24, 27] (6B11), IFN-, IL-4, IL-5, IL-10,
nd IL-13 were obtained from BD-Pharmingen (Ox-
ord, UK). The expression of cell surface or intracellular
ntigens by fresh or cultured PBMCs or purified PBMC
ubsets was detected by mAb staining and four-color
low cytometry (FACSCalibur, Becton Dickinson, Ox-
ord, UK) with CellQuest software (Becton Dickinson).
n Vitro Stimulation and Expansion of T Cells
BMCs or enriched PBMC subsets were suspended in
omplete RPMI medium (RPMI 1640 containing 25
M HEPES, 2 mM L-glutamine, 50 g/ml streptomy-
in, 50 U/ml penicillin, and 10% fetal calf serum) at a
ensity of 0.5  106 cells/ml and stimulated for up to
20 hours with either 10 ng/ml phorbol myristate ace-
ate (PMA) plus 1 g/ml ionomycin, or with anti-CD3
Ab (0–3 g/ml HIT3a; BD-Pharmingen Erembadege,
elgium) that was bound to microwell plates by incu-
ation at 37°C for 4 hours in 0.1 M Na2HPO4, pH 9.
or longer-term stimulation and expansion of T cells,
BMCs were suspended in complete RPMI medium
ontaining 5 g/ml phytohemagglutinin (PHA, Sigma-
ldrich, Dublin, Ireland), and 25 ng/ml recombinant
uman IL-2 (National Cancer Institute, Frederick, Mary-
and) was added 2 days later and at 4–5 day intervals
hereafter. After 12–14 days, the cells were restimulated
ith PHA and an equal number of irradiated (5000 rad)
llogeneic PBMCs and fed with IL-2 as above. The
ultures were analyzed by flow cytometry or separated
nto CD56 and CD56 subsets on day 28.
urification of CD56 and CD56 T Cells
D56 and CD56 T cells were purified from fresh
BMCs or PBMCs that were stimulated twice with PHA
nd cultured with IL-2, as described above, which re-
ulted in the death of all non-T (CD3) cells and selec-
ive expansion of CD56 T cells (see results). CD56
nd CD56 cells were then purified using CD56 mi-
robeads (Miltenyi Biotec, Gladbach Bergische, Ger-
any). The purities of enriched fractions were deter-
m
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865Cytokine Profiles of CD56 T Cellsined by flow cytometry, and only preparations that
ielded purities of 	98% were used in functional
tudies.
ytotoxicity Assays
HC-unrestricted cytotoxicity by CD56 and CD56
cells, purified as above, was assayed in 4-hour
1chromium-release assays [25] using K562 cells as
argets.
nalysis of Cytokine Production
he release of IFN-, IL-13, and IL-10 into supernatants
f stimulated cells (0.5  106/ml) over 3 days was
uantified by enzyme linked immunosorbent assay
ELISA) by using antibody pairs and recombinant cyto-
ine standards purchased from R&D Systems (Abingdon,
K).
Intracellular expression of IFN-, IL-4, IL-5, IL-10,
nd IL-13 by PBMC subsets was detected by flow cy-
ometry after stimulating the cells with PMA and iono-
ycin or anti-CD3 mAb in the presence of brefeldin A
10 g/ml, Sigma-Aldrich), an inhibitor of protein trans-
ocation from the endoplasmic reticulum to the Golgi
pparatus. Cells were then stained with mAbs specific for
urface CD3 and CD56, fixed with 4% paraformalde-
yde, and permeabilized with 0.2% saponin (Sigma-
ldrich) before adding the anti-cytokine mAbs [25]. As
ontrols, unstimulated cells were treated similarly.
tatistical Analysis
ean frequencies of lymphocyte subsets and mean cyto-
ine levels were compared using the paired Student’s t-
est and p values of 
0.05 were considered significant.
ESULTS
D56 Expression
y T Cells Is Induced by Activation
low cytometric analysis of freshly isolated PBMCs (Fig-
re 1A) from 33 healthy donors indicated that CD56 was
xpressed by 0.7%–14.2% (mean 5%) of CD3 cells. Up
o 6.9% (mean 1.9%) of CD56 T cells, compared with
.5 % (range 1.7%–24.7%) of NK cells, expressed high
evels of CD56 (CD56bright cells). About 50% (range
7.6%–80%) of CD56 T cells expressed the CD8
oreceptor, whereas the remainder expressed CD4 or
ouble-negative CD4CD8 phenotypes in approxi-
ately equal proportions. Of the CD56 T cells, 14.4%
range 9.3%–27.9%) had  TCRs, compared with
.6% of CD56 T cells. A higher proportion (1.6%) of
D56 T cells (range 0.6%–2.5%) had invariant
24J18 TCR chains compared with 0.02% of
D56 T cells (0.007%–0.03%, Table 1 and data nothown). 1The inducibility and stability of CD56 expression by
cells was examined by stimulating PBMCs with plate-
ound anti-CD3 mAb and analyzing CD56 expression
y CD3 cells at intervals up to 120 hours. Figure 1B
llustrates that short-term (5-day) T-cell activation with
nti-CD3 mAb alone resulted in a gradual increase in the
ercentages of T cells that expressed CD56, from 6%–
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IGURE 1 CD56 is induced on peripheral blood T cells by
ctivation in vitro. (A) Representative flow cytometric dot plot
emonstrating the expression of CD56 by CD3 and CD3
ymphocytes in fresh peripheral blood mononuclear cells (PB-
Cs). (B) Kinetics of CD56 positivity of CD3 and CD3
BMCs after stimulation with 0.3 g/ml plate-bound anti-
D3 monoclonal antibody (means of 9 samples). (C) Kinetics
f CD56 and CD161 expression by peripheral T cells after
timulation with phytohemagglutinin and culture with inter-
eukin (IL)-2 (means of three samples). (D) Representative flow
ytometric dot plots illustrating expression of CD56 by T cells
efore (left) and after (right) expansion for 28 days with
hytohemagglutinin and IL-2 when PBMCs that were de-
leted of CD56 T cells were used as starting material. Error
ars illustrate standard errors of the means.7.9% (threefold, means of nine samples). No expansion
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866 J. Kelly-Rogers et al.f overall cell numbers was observed. After repeated
timulation with PHA and culturing with IL-2, total cell
umbers increased by a mean factor of 4.2, and the mean
requencies of CD56 T cells rose from 3%–26.2%
ninefold), whereas the frequencies of T cells expressing
nother NKR, CD161, remained constant (means of
hree samples, Figure 1C). This amounts to a mean
7-fold expansion of CD56 T cells. To determine
hether these expansions of CD56 T cells are a result of
he induction of CD56 expression by activated CD56 T
ells or the selective expansion of CD56 T cells, PBMCs
ere depleted of CD56 T cells by using mAb-coated
agnetic beads and were expanded with PHA and IL-2.
fter 28 days, CD56 was expressed by a mean of 37% of
cells, where purified CD56 T cells were used as
tarting material (Figure 1D). These results provide ev-
dence that CD56 can be induced on T cells by
ctivation.
henotypes of Activation-Induced CD56 T Cells
D56 T cells were expanded from PBMCs by subject-
ng them to two rounds of stimulation with PHA and
ulturing them with IL-2. Flow cytometry was used to
ompare the frequencies of CD4, CD8 and ,  and
24J18 TCR expression by activation-induced
D56 T cells with those of CD56 T cells in fresh
lood. Table 1 demonstrates that, whereas a mean of
3% of CD56 T cells in fresh blood express CD4, this
oreceptor was not present on activation-induced CD56
cells, all of which expressed CD8 (mean 74%) or
ouble-negative CD4CD8 (26%) phenotypes.
ctivation-induced expansion of CD56 T cells was not
ssociated with expansions of  T cells, which ac-
ounted for 14% of CD56 T cells in fresh blood com-
ared with 4% of induced CD56 T cells. In contrast,
D1d-restricted NKT cells expressing invariant
24J18 TCRs and CD56 were expanded by activa-
ABLE 1 Phenotypic properties of freshly isolated hu
induced by two rounds of stimulation with
Cell-surface phenotype Percent of fresh CD56T cells (m
D4CD8 23 (7-41)
D8CD4 52 (18-80)
D4CD8 15 (10-34)
D4CD8 0.6 (0-1.0)
TCR 86 (72-91)
TCR 14 (9.3-28)
24J18 TCR 1.6 (0.6-2.5)
bbreviations PHA  phytohemagglutinin; IL  interleukin.
Data are means and ranges of 4-15 samples.ion, these TCR chains being present on 2% of induced lD56 T cells and 1.6% of CD56 T cells from fresh
lood (Table 1).
D56 T Cells Display Reduced Proliferative
apacity and Enhanced MHC-Unrestricted
ytotoxicity Compared With CD56 T Cells
D56 and CD56 T cells were purified from freshly
solated PBMCs, and 5  106 cells of each type were
xpanded for 28 days with PHA and IL-2, as described
bove. At various time intervals, the number of viable
ells was determined. Figure 2A illustrates that purified
D56 T cells underwent a mean 17-fold expansion,
hereas CD56 T cells expanded about fourfold in this
ime, indicating that they have either a reduced prolif-
rative capacity or an increased sensitivity to apoptosis.
D56 and CD56 T cells purified from PBMCs that
ere expanded with PHA and IL-2 were used as effectors
n 51chromium-release cytotoxicity assays against the
562 target cell line. Figure 2B illustrates that CD56
cells displayed moderate cytotoxicity, giving a mean
pecific lysis of 9% at effector/target ratios of 50:1,
hereas CD56 T cells displayed negligible (0.23%)
ytotoxicity.
inetics of Activation Marker Expression by
esting and Activated CD56 and CD56 T Cells
low cytometric analysis of freshly isolated PBMCs re-
ealed that the early activation marker, CD69, was not
xpressed by resting CD56 T cells, but was present on
p to 55% (mean 24%) of CD56 T cells (Figure 3).
ithin 1 hour of culture with PMA and ionomycin,
oth cell subsets expressed CD69, and by 24 hours this
ctivation marker was expressed by all lymphocytes (data
ot shown). Significantly higher frequencies of CD56
mean 63.9%) compared with CD56 (mean 31.1%, p 

.001) T cells upregulated CD69 in response to anti-
D3 mAb stimulation, peaking at 24 hours for both
peripheral blood CD56 T cells and CD56 T cells
A and culture with IL-2a
nd range)
Percent of activation-induced CD56 T cells
(mean and range)
0.6 (0-1.5)
74 (61-88)
25.9 (12-40)
0.3 (0-0.9)
96 (93-98)
4 (1.7-7.4)
2 (1.3-2.7)man
PH
ean aymphocyte subsets (Figure 3). CD25 was found to be
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867Cytokine Profiles of CD56 T Cellsxpressed by less than 17% of resting CD56 and
D56 T cells, but its expression was induced on 100%
f T cells within 72 hours of activation with PMA and
onomycin (data not shown), and 75.1% and 64% of
D56 and CD56 T cells, respectively, stimulated
ith anti-CD3 mAb for 96 hours (Figure 3). HLA-DR
as expressed by 
5% of freshly isolated PBMCs but
as induced on about 50% of CD56 and CD56 T
ells in response to 48 hours stimulation with PMA and
onomycin (data not shown), and about 10% of both cell
opulations following anti-CD3 mAb stimulation (Fig-
re 3). CD45RO was expressed by around 29% of resting
D56 and CD56 T cells. This antigen was slowly
nduced on CD56 and CD56 T cells by stimulation
ith PMA and ionomycin over a 5-day period, reaching
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IGURE 2 CD56 T cells display reduced proliferative
apacity and enhanced major histocompatibility complex–un-
estricted cytotoxicity compared to CD56 T cells. (A) Viable
ell numbers recovered at various times after stimulation of 5
106 CD56 or CD56 T cells purified from PBMCs. (B)
pecific lysis of K562 target cells by CD56 and CD56 T
ells purified from PBMCs expanded with phytohemaggluti-
in and IL-2. Results are means of three experiments. E/T 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eans.aximum frequencies of 60% of CD56 T cells and o0% of CD56 T cells (not shown). However, CD45RO
as not induced on either cell type by anti-CD3 activa-
ion (Figure 3).
D56 T Cells Release IFN- and IL-13, but Not
L-10, Upon CD3 Stimulation
BMCs were expanded with PHA and IL-2, and CD56
nd CD56 T cells were purified by selection with
Ab-coated magnetic beads. Similar numbers of CD56
nd CD56 T cells were stimulated with anti-CD3 mAb
ound to microwell plates at varying concentrations.
fter 24, 48, or 72 hours, supernatants were collected
nd assayed for IFN-, IL-13, and IL-10 by ELISA.
igure 4 demonstrates that IFN- release by both lym-
hocyte subsets was detectable 24 hours after stimulation
ith 0.03–3 g/ml anti-CD3 mAb. Consistently higher
mounts of IFN- were released by CD56 T cells
ompared with similar numbers of CD56 T cells after
8 hours (p  0.04) and 72 hours (p  0.01). The
inetics of IFN- secretion by both cell types was sim-
lar, increasing gradually from 0–72 hours. IL-13 was
eleased by both CD56 and CD56 T cells in similar
mounts and with similar kinetics after stimulation with
.03–3 g/ml anti-CD3 mAb (Figure 4). Purified
D56 T cells consistently released moderate amounts
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868 J. Kelly-Rogers et al.f IL-10 at 48–72 hours after stimulation with 0.03–3
g/ml anti-CD3 mAb, whereas little or no IL-10 was
ecreted by resting or stimulated CD56 T cells (Figure
). The differences in IL-10 levels released by CD56
nd CD56 T cells were significant at 48 hours (p 
.006) and 72 hours (p  0.01) after stimulation. These
ata indicate that CD56 T cells can release Th1 and
h2 cytokines upon stimulation, but unlike CD56 T
ells, they cannot be induced to release the regulatory
ytokine IL-10 by TCR stimulation.
D56 T Cells Rapidly Express Intracellular
ytokines Upon Activation
igure 4 illustrates that CD56 T cells release IFN-
nd IL-13, whereas CD56 T cells can release IFN-,
L-13, and IL-10 within 24 hours of stimulation with
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IGURE 4 Quantification of cytokine secretion by CD56
nd CD56 T cells after stimulation with plate-bound anti-
D3 monoclonal antibody (mAb). Left, mean levels of inter-
eron-gamma (IFN-) and IL-13 released after 48 hours and
L-10 released after 72 hours, after stimulation with 0–3
g/ml anti-CD3 mAb as measured by enzyme linked immu-
osorbent assay (means of six experiments). Right, kinetics of
FN-, IL-13, and IL-10 release after stimulation with 0.3
g/ml anti-CD3 mAb (means of three experiments). Error bars
llustrate standard errors of the means.nti-CD3 mAb. Since CD56 T cells display properties 1f innate lymphocytes, it is possible that they become
ctivated to release cytokines in the first few hours after
ctivation. We investigated the early kinetics of intra-
ellular cytokine expression by CD56 and CD56 T
ells within freshly isolated PBMCs from five donors by
sing flow cytometry (Figure 5A). No IFN- was ex-
ressed by unstimulated cells. IFN- was expressed by
ignificant proportions of CD56 T cells (mean 30.3%)
nd CD56 T cells (mean 10%) within 2–6 hours of
BMC stimulation with PMA and ionomycin (Figure
B). Lower proportions of CD56 T cells (mean 4.5%)
nd CD56 T cells (mean 1.2%) expressed IFN- after
timulation with anti-CD3 mAb. The proportions of
D56 T cells that produced IFN-, after both types of
timulation, were significantly higher than those of
D56 T cells (p  0.004 for PMA and ionomycin
timulation and p  0.03 for anti-CD3 mAb stimula-
ion). The mean intensities of fluorescence staining for
FN- were similar for CD56 and CD56 T cells,
uggesting that similar amounts of IFN- were produced
y both cell types (Figure 5A).
Significant frequencies of CD56 T cells (mean 8.4%)
nd CD56 T cells (mean 1.5%) produced IL-4 after
BMC stimulation for up to 6 hours with PMA and
onomycin, and lower percentages (means 5.2% and
.9%, respectively) produced IL-4 after anti-CD3 mAb
timulation (Figure 5B). Consistently higher frequencies
f CD56 T cells produced IL-4 compared with CD56
cells (p  0.03 for PMA and ionomycin and p  0.02
or anti-CD3 mAb). Intracellular IL-13 was also detected
n significantly greater frequencies of CD56 T cells
ompared with CD56 T cells (after 4 hours means 8.4%
nd 1.5%, respectively, p  0.01 for PBMC stimulation
ith PMA and ionomycin and means 3.0% and 0.5%,
espectively, p  0.001 for stimulation with anti-CD3
Ab, Figure 5B). IL-5 and IL-10 were expressed by very
ow proportions (
3%) of CD56 and CD56 T cells
fter stimulation of the PBMCs with PMA and ionomy-
in or anti-CD3 mAb (Figure 5B).
ISCUSSION
D56 T cells belong to a heterogenous group of human
cells that express various stimulatory, costimulatory,
nhibitory, and adhesion receptors that control NK cell
ctivity [3–5, 33–35]. T cells with NKRs, including
D56 T cells, are often present in cultures of stimu-
ated T cells [4, 11, 13–17], and they frequently express
emory phenotypes [2, 36, 37]. They can be activated
y TCR ligation and by antigen-nonspecific signals
hrough NKRs and cytokine receptors [4, 11, 25, 33–
5] and display potent MHC-unrestricted cytotoxicity
gainst a range of tumor cells in vitro and in vivo [3, 11,
2, 18, 19, 25].
p
p
i
[
m
b
d
c
t
r
b
f
v
i
f
a
p
i
c
m
h
P
g
W
i
F
f
R
a
I
a
I
869Cytokine Profiles of CD56 T CellsMany NKR T cells can recognize nonprotein com-
onents of pathogens and host cells. Such “innate lym-
hocytes” include NKT cells, which recognize glycolip-
ds presented by the MHC class I-like molecule CD1d
27, 38], and  T cells, which respond to soluble
etabolites, heat shock proteins, or glycolipids presented
y CD1c [26]. NKT cells and  T cells most notably
isplay rapid Th1, Th2, and/or regulatory cytokine se-
retion and are thought to be important for the initia-
ion, polarization, and regulation of adaptive immune
esponses [24, 39–42]. Defects in cytokine production
y NKT cells and  T cells have been associated with
ailure to eliminate pathogens and tumors and the de-
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unctional similarities (responsiveness to innate cytokines
nd MHC-unrestricted cytotoxicity) to these innate lym-
hocytes [3, 4, 11, 12, 18, 19, 25, 33, 34] and are altered
n disease [23, 28–32], but it is not clear whether these
ells can similarly initiate and/or regulate adaptive im-
une responses.
In the present study, we confirm previous reports that
uman CD56 T cells can be expanded from fresh
BMCs by TCR-mediated activation, particularly when
rown in the presence of exogenous IL-2 [4, 11, 13–17].
e found that a single CD3/TCR stimulation of PBMCs
n the absence of added growth factors resulted in three-
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870 J. Kelly-Rogers et al.ell numbers. Expansion of PBMCs by two rounds of
HA stimulation and culturing with IL-2 resulted in a
ean 37-fold increase in CD56 T cell numbers, ex-
anding from 3%–27% of all T cells in 28 days. Con-
istent with previous reports that CD56 is present on T
ells at a later stage of differentiation [13], purified
xpanded CD56 T cells displayed a lower proliferative
otential than CD56 T cells from the same cultures. As
reviously reported [11, 25], CD56 T cells, only, were
apable of killing the NK-sensitive target cell line,
562, but this cytolytic activity was less potent than
hat of NK cells. We found that PHA and IL-2–induced
xpansions of CD56 T cells are the result both of the
nduction of CD56 expression by CD56 T cells and of
he proliferation of CD56 T cells. Expansion of PBMCs
hat were first depleted of CD56 T cells with PHA and
L-2 resulted in the expression of CD56 by a mean of
7% of T cells after 28 days. This suggests that CD56
an be induced on T cells by activation. It is possible that
he CD56 T cells in these cultures arose from expan-
ions of small numbers of contaminating CD56 T cells;
owever, we feel that this is unlikely since CD56 T
ells were found to proliferate less vigorously than
D56 T cells.
Phenotypic analysis of CD56 T cells generated by
itogen activation and culturing with IL-2 in vitro in-
icated that CD56 is induced on CD8 and double-
egative CD4CD8 T cells, but not CD4 T cells,
ven though CD56 T cells expressing CD4 were
resent in fresh blood. CD4, CD8, and double-
egative CD56 T cells are also present in the liver [6,
] and the small intestine [8–10]. CD56 was induced on
 T cells and NKT cells expressing the invariant
24J18 TCR but less frequently on  T cells, even
hough CD56  T cells are present in significant
umbers in blood. The phenotypic differences between
aturally occurring and ex vivo activation-induced
D56 T cells indicate that different signals are re-
uired for the expansion of different populations of
D56 T cells, and the changes in CD56 T cell
umbers in disease [23, 28–32] may reflect changes in
ubpopulations of this group of cells.
Examination of activation marker expression by
reshly isolated PBMC subsets by flow cytometry re-
ealed that the early activation marker, CD69, is ex-
ressed by greater frequencies of CD56 T cells com-
ared with CD56 T cells, but CD25, HLA-DR, and
D45RO are expressed by similar proportions of each
ymphocyte subset. Each activation marker examined
as induced on a proportion of CD56 and CD56 T
ells with similar kinetics after treatment with PMA and
onomycin, but CD69 and CD25, only, were induced on
ignificant proportions of both T cell subsets following
nti-CD3 mAb stimulation. Since both CD56 and cD56 T cells in fresh PBMCs include cells that are
ositive and cells that are negative for activation mark-
rs, and since both T cell subsets demonstrate similar
inetics of activation marker expression following acti-
ation, it is possible that CD56 T cells in fresh blood
nclude both naive and effector T cells. Further studies
re required to ascertain whether induced CD56 T cells
xpress memory cell phenotypes. Our observations also
uggest that CD56 T cells are not activated more
apidly than CD56 T cells.
We examined the cytokine secretion profiles of human
D56 T cells to determine whether they display the
apid Th1/Th2/regulatory cytokine secretion properties
hat are characteristic of innate lymphocytes, such as
KT cells and  T cells [24, 39–42]. CD56 and
D56 T cells were purified from PHA and IL-2–
xpanded PBMC cultures by mAb-coated magnetic bead
election. Similar numbers of purified CD56 and
D56 T cells were given a single stimulation with
arying amounts of crosslinking anti-CD3 mAb, and
amples of supernatant were removed at various times
oststimulation for analysis of IFN-, IL-13, and IL-10
evels by ELISA. As previously reported for sorted CD8
D56 T cells [3, 5], CD56 T cells were found to
elease higher levels of the Th1 cytokine, IFN- than did
imilar numbers of CD56 T cells. We found that the
inetics of IFN- release were similar for both lympho-
yte subsets, with maximal levels detectable after 48
ours. Furthermore, the strengths of the stimuli, based
n the concentrations of anti-CD3 mAb used, required to
nduce IFN- release were the same for CD56 and
D56 T cells. Similar amounts of the Th2 cytokine,
L-13, were released by CD56 and CD56 T cells
ollowing the same stimulus strengths and similar kinet-
cs. However, CD56 T cells could not be induced to
elease IL-10, whereas CD56 T cells consistently re-
eased significant amounts of this regulatory cytokine
ithin 48 hours of stimulation with anti-CD3 mAb. The
ifferences in IL-10 secretion by CD56 and CD56 T
ells were significant. Our data indicate that CD56 T
ells can promote Th1 or Th2 responses but are unlikely
o regulate them via IL-10 secretion.
We investigated whether CD56 T cells are more
ikely to produce cytokines than CD56 T cells at the
arly stages (2–24 hours) after stimulation, by activating
resh PBMCs in the presence of brefeldin A and deter-
ining the percentages of CD56 and CD56 T cells
hat express intracellular IFN-, IL-4, IL-5, IL-13, or
L-10, by flow cytometry. We found that IFN-, IL-4
nd IL-13, but not IL-5 or IL-10, were expressed by
ignificant proportions of CD56 T cells within 2 hours
f stimulation with either PMA and ionomycin or anti-
D3 mAb. Significantly lower proportions of CD56 T
ells expressed these cytokines. IFN- and IL-4 have
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871Cytokine Profiles of CD56 T Cellsreviously been shown to be expressed by higher fre-
uencies of CD56 compared with CD56 T cells upon
hours of stimulation in fresh peripheral blood [4] and
iver [15, 25] mononuclear cells. In contrast, Loza et al.,
sed flow cytometry to demonstrate that IFN- expres-
ion is higher, but IL-4 and IL-13 expression is lower, in
D56 T cells compared with CD56 T cells in cultures
hat were matured with IL-2, IL-12, IL-18, and/or
FN-, indicating that the culture conditions used to
enerate CD56 T cells are likely to influence the cyto-
ine profiles [13]. For this reason, we avoided using Th
ell polarizing cytokines, such as IL-12 or IFN-, to
xpand CD56 T cells, as was done for the generation of
ntitumor cytokine-induced killer cells [11, 13–17]. An-
ossi and coworkers have demonstrated that murine and
uman CD8 T cells that express other NKRs (Ly49 or
iller immunoglobulinlike receptors), display reduced
requencies of IFN- and TNF- expression compared
ith NKR CD8 T cells [43, 44], whereas Kamba-
ashi et al. reported that murine influenza-specific
KR T cells produce IFN- in response to influenza
ntigens [45].
Our combined ELISA and flow cytometry results in-
icate that human CD56 T cells are more likely to
roduce Th1 (IFN-) and Th2 (IL-4 and IL-13) cyto-
ines than CD56 T cells at early times poststimulation,
hat CD56 T cells release higher amounts of IFN- but
imilar amounts of IL-13 compared with CD56 T cells
fter 48 hours, and that CD56 T cells do not produce
L-5 or IL-10. The apparent differences in cytokine pro-
uction as detected by flow cytometry and ELISA may
eflect different cytokine-mediated functions at different
tages of an immune response. Cytokines released at an
arly stage after activation are likely to be directed into
he immunologic synapse between the T cell and
ntigen-presenting cell, and very small quantities of
ytokine may be sufficient to saturate this microenviron-
ent. In contrast, the large amounts of cytokine that
ccumulate in supernatants over 48 hours, and that are
etectable by ELISA, are more likely to target multiple
ells in the region of the T cell. These two scenarios of
ytokine secretion are mediated by two directionally
istinct export pathways [46]. The enhanced ability of
ome CD56 T cells to produce cytokines at an early
tage suggests that they can function as innate lympho-
ytes like CD1-restricted NKT cells and  T cells,
hich can stimulate maturation of dendritic cells [47,
8] into antigen-presenting cells as well as releasing
h1/Th2 cytokines.
Our data indicate that CD56 expression can be in-
uced on CD56 T cells by TCR-mediated activation,
nd that the expression of this marker is associated with
ltered cytokine secretion profiles in addition to the
cquisition of MHC-unrestricted cytotoxic activity. Thecquisition of MHC-unrestricted cytotoxic activity by
D56 T cells would allow them to kill target cells in
n antigen-nonspecific manner, perhaps as a means to
ombat pathogens and tumors that undergo antigenic
rift and can evade conventional MHC-restricted T cells.
heir ability to release IFN- and IL-13 in response to
CR stimulation indicates that they can also promote
h1 and Th2 responses. In contrast to CD56 T cells,
ctivation-induced CD56 T cells do not secrete IL-10.
hus, CD56 T cells may emerge in parallel with in-
ucible regulatory T cells [49] and may provide a
ounter-regulatory cell population that can activate
daptive immune responses in certain tissues. This could
ccur in the liver and intestine, where tolerance is fa-
ored over active immunity and where CD56 T cells
re particularly abundant [6–10]. The ease by which
D56 T cells can be expanded from PBMCs supports
heir use as possible therapeutic modulators of immune
esponses in infectious and immune-mediated diseases,
n addition to their potential as antitumor cytotoxic
ffector cells.
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